Fecal calprotectin is a useful marker for defining small bowel endoscopic remission in Crohn’s disease
1. In patients with Crohn’s disease (CD), fecal calprotectin (FC) was a useful biomarker for monitoring small bowel lesions and ...
Tag: Crohn’s Disease
Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis
1. Rectoscopy alone for evaluation of endoscopic and histologic remission of ulcerative colitis (UC) had good accuracy and is sufficient ...
Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn’s disease
1. Intestinal ultrasound (IUS) and magnetic resonance imaging (MRI) were effective imaging modalities for the assessment of the radiologic response ...
Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia
1. In postmenopausal patients with ulcerative colitis (UC) or Crohn’s disease (CD), approximately one-third had osteoporosis while approximately 40% had ...
Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
Fecal Microbiota, live-jslm may be an effective means of preventing Clostridiodes difficile infections in patients with inflammatory bowel disease
1. The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection (rCDI) in patients ...
5-Aminosalicylic Acid may not be an effective combination with ustekinumab for inflammatory bowel disease
1. Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in ...
Glucagon-like peptide 1 receptor agonists may decrease rates of inflammatory bowel disease flares
1. The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...
Sarcopenia is a risk factor for postoperative complications in adults with inflammatory bowel disease
1. Sarcopenia is associated with an increased risk of adverse postoperative outcomes in older adults with inflammatory bowel disease (IBD). ...
Risankizumab is superior to ustekinumab for endoscopic remission of Crohn’s disease
1. In this randomized controlled trial, risankizumab was non-inferior to ustekinumab in terms of clinical remission at 24 weeks in ...